University College London Hospitals NHS
NHS Foundation Trust

Performance in Initiating and Delivering (PID) Clinical Research
UCLH Performance in Approving and Recruiting to Research
June 2017

Since July 2012, providers of NHS services have been providing data on performance in initiating and delivering clinical research. Data for studies which have received NHS approval (called NHS Permission) in the previous 12 months is submitted quarterly to the National Institute for Health Research (NIHR). Below, a summary of performance submitted by UCLH in Quarter 1 (2017/18) for studies where UCLH was selected as a site over the past year.

Providers are asked to publish details of the length of time taken to approve clinical trials from the point at which NHS Permission is applied for through to the recruitment of the first participant. This period is known as the initiation stage and the NIHR has assigned a benchmark target of 70 days.

Providers also submit information on those Commercially Sponsored Trials, which have closed to recruitment in the year and whether the trial has achieved its anticipated total recruitment target. The period between recruitment of the first participant and reaching the total recruitment target is known as the delivery stage. Each quarter, UCLH will update this information with the most recent studies. The data is correct as of end of June 2017.

For Further information on PID reporting, please visit the NIHR pages at:
http://www.nihr.ac.uk/policy-and-standards/Performance-in-initiating-and-delivering-research.htm

Initiating Clinical Research – HRA Approval

ID	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Date of First Patient Recruited	Benchmark Met	Reasons for delay correspond to:
1	16/LO/1024	195085	Safety and efficacy of Belimumab after B cell depletion therapy (BCDT) in systemic lupus erythematosus	06/09/2016	27/09/2016	11/10/2016		12/10/2016		14/10/2016	14/10/2016	Yes	
2	16/HRA/3375	204425	A Pilot Study Assessing the Therapeutic Potential of a Vibratory Positive Expiratory Pressure (PEP) Device in the Treatment of Voice Disorders	26/08/2016	13/09/2016	26/08/2016		19/09/2016		19/09/2016	03/10/2016	Yes	
3	16/EE/0463	214371	COMPLEEMENT-1: An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and postmenopausal women with hormone receptor positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease		16/03/2017			16/03/2017		16/03/2017	06/04/2017	Yes	

4	17/YH/0050	207335	An Evaluation of Mindfulness Based Stress Reduction Groups for Adolescents and Young Adults with Crohn?s disease and Ulcerative Colitis	16/02/2017	24/03/2017	02/03/2017		11/04/2017		12/04/2017	25/04/2017	Yes	
5	16/LO/2186	188540	A randomised phase I/II study of Intensity Modulated Arc Therapy techniques in abdominal neuroblastoma		17/01/2017	17/01/2017		21/02/2017		21/02/2017	01/03/2017	Yes	
6	16/YH/0288	198946	An Open, Qualitative, Prospective, Multicenter Trial of a Novel Transanal Irrigation System in Spinal Cord Injured Patients	27/06/2016	22/08/2016	12/08/2016		23/09/2016		30/09/2016	24/02/2017	No	Sponsor
7	16/NE/0279	198051	Risk-stratified sequential Treatment with Ibrutinib and Rituximab (IR) and IR-CHOP for De-novo post-transplant Lymphoproliferative disorder (PTLD)	04/01/2017	24/03/2017			11/04/2017		11/04/2017	16/05/2017	Yes	
8	16/LO/0720	143566	Feasibility of home based training and falls management program in people with inherited peripheral neuropathy	10/08/2016	23/09/2016	10/08/2016		25/11/2016		28/11/2016	28/11/2016	Yes	
9	15/LO/1284	179637	DOSE-ESCALATING AND COHORT EXPANSION SAFETY TRIAL OF TISSUE FACTOR SPECIFIC ANTIBODY DRUG CONJUGATE TISOTUMAB VEDOTIN (HUMAX?-TF-ADC) IN PATIENTS WITH LOCALLY ADVANCED AND/OR METASTATIC SOLID TUMORS KNOWN TO EXPRESS TISSUE FACTOR	03/02/2017	06/02/2017			05/04/2017		07/04/2017	24/04/2017	No	Sponsor
10	16/SC/0376	202786	Testing Radical prostatectomy in men with prostate cancer and oligoMetastases to the bone: a randomised controlled feasibility trial		27/02/2017	10/10/2016		10/03/2017		13/03/2017	19/05/2017	No	Neither

11	16/LO/1612	201997	Prospective Follow-up Study for Patients who Completed Study ALX0681-C301 (HERCULES) to Evaluate Long-term Safety and Efficacy of Caplacizumab (Post-HERCULES)	28/09/2016	17/10/2016	16/11/2016		14/12/2016		15/12/2016	06/01/2017	No	Sponsor
12	16/LO/1755	209250	Evaluation of the effect of Duodenal Mucosal Resurfacing (DMR) using the Revita System in the treatment of Type 2 diabetes (T2D)- Revita 2 ? C-30000		31/01/2017	24/01/2017		01/03/2017		02/03/2017	28/04/2017	No	Neither
13	16/LO/1341	191779	A Phase IIA Prospective, Single-Centre, Open Label Clinical Trial to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of Ambroxol in Patients with Parkinson Disease	01/09/2016	13/10/2016	14/10/2016		21/11/2016		23/11/2016	11/01/2017	No	Sponsor
14	16/LO/1450	202124	A Phase 3, Multicenter, Randomized, Double Blind Study of Bortezomib and Dexamethasone in Combination with Either Venetoclax or Placebo in Subjects with Relapsed or Refractory Multiple Myeloma Who are Sensitive or Na?ve to Proteasome Inhibitors	02/06/2016	31/08/2016	11/10/2016		21/10/2016		24/10/2016	30/11/2016	No	NHS Provider
15	16/LO/1782	213379	Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)		23/11/2016	29/11/2016		08/02/2017		09/02/2017	01/03/2017	No	Sponsor
16	15/WM/0268	180518	Randomised, open label study of rituximab/ibrutinib vs rituximab/chemotherapy in older patients with untreated mantle cell lymphoma	31/01/2017	01/02/2017	26/08/2016		27/04/2017		08/05/2017	23/05/2017	No	Sponsor

17	16/EE/0243	207331	A 6-Month, Multicenter, Phase 3, Open-Label Extension Safety Study Of OTO-104 Given At 3-Month Intervals by Intratympanic Injection in Subjects with Unilateral Meniere's Disease	22/09/2016	12/10/2016	01/08/2016		30/11/2016		20/12/2016	06/02/2017	No	Sponsor
18	16/LO/2106	215913	A Phase IB Combination Study of Rucaparib (CO-338) and Atezolizumab (MPDL3280A) in Patients with Solid Tumours and advanced gynaecologic cancers, with a focus on Ovarian Cancer	27/10/2016	09/12/2016	13/02/2017		29/03/2017		03/04/2017	07/04/2017	No	Sponsor
19	16/LO/1677	191232	A phase II, multi-centre, non-randomised, molecularly stratified trial for NSCLC patients to study tumour heterogeneity using genomic analysis	27/10/2016	16/01/2017			18/04/2017		18/04/2017	16/05/2017	No	Sponsor
20	16/LO/1744	211158	Safety and tolerability of single and repeated doses of ODM-203: An Open-label, non-randomised, uncontrolled, dose escalation, multicentre, first-in-human study in subjects with advanced solid tumours	23/08/2016	20/09/2016	05/12/2016		13/12/2016		16/12/2016	23/01/2017	No	Sponsor
21	16/SC/0341	204761	A Phase 2, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with Relapsed or Refractory Malignant Mesothelioma with BAP1 Loss of Function	03/06/2016	15/08/2016	11/08/2016		29/11/2016		05/12/2016	19/12/2016	No	NHS Provider
22	17/LO/0169	214075	Effect of MD1003 in progressive multiple sclerosis: a randomized double blind placebo controlled study	14/11/2016	13/02/2017	21/04/2017		09/05/2017		26/05/2017	21/06/2017	No	Neither

23	16/NE/0159	205953	A Phase 1b/2a Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety and Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-220 Monotherapy and in Combination with Dexamethasone in Subjects with Relapsed and Refractory Multiple Myeloma	14/06/2016	06/07/2016	13/10/2016		15/09/2016		26/10/2016	16/11/2016	No	Neither
24	16/EM/0408	211983	A Phase 2, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of GS-5745 Combined with Nivolumab versus Nivolumab Alone in Subjects with Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma	18/07/2016	19/09/2016			14/12/2016		29/12/2016	01/02/2017	No	Sponsor
25	16/LO/1776	191954	First-in-man feasibility study to assess the safety of TIPS microspheres in perianal fistulas		18/01/2017	17/01/2017		17/02/2017		17/02/2017	06/06/2017	No	Sponsor
26	16/SC/0418	198404	The clinical effectiveness of 5% Carbamide Plus, 10% Carbamide Plus compared to two commercially available 10% Carbamide peroxide products: a double blind randomised placebo controlled clinical trial		07/12/2016	07/12/2016		03/02/2017		22/02/2017	02/05/2017	No	Sponsor
27	16/WM/0437	206855	ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): A Phase 3 Multicenter, Randomized Study of Rucaparib versus Chemotherapy in Patients with Relapsed, BRCA-Mutant, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer		05/10/2016	15/12/2016		26/01/2017		08/02/2017	28/02/2017	No	Sponsor

28	16/LO/1636	172808	A prospective randomized multi-center study comparing endoscopic pneumodilation and per oral endoscopic myotomy (POEM) as treatment of idiopathic achalasia		03/11/2016	03/11/2016		27/01/2017		27/01/2017	31/03/2017	No	Sponsor
29	16/WM/0439	211177	A Multicenter, Randomized, Double-Blind, Sham-Controlled Clinical Investigation of the EndoStim? Lower Esophageal Sphincter (LES) Stimulation System for the Treatment of Gastroesophageal Reflux Disease (GERD)	17/06/2016	12/12/2016	12/12/2016		13/02/2017		07/04/2017	23/05/2017	No	Neither
30	16/NE/0370	214375	A Phase III Double-blind, Randomized, Placebo-Controlled Study assessing the Efficacy, Safety and Tolerability of Idebenone in Patients with Duchenne Muscular Dystrophy Receiving Glucocorticoid Steroids		06/01/2017	29/12/2016		14/03/2017		20/03/2017	22/06/2017	No	Sponsor
31	16/NE/0342	213304	A Phase 1 Dose-escalation Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)		11/10/2016	24/01/2017		02/02/2017		15/02/2017	05/04/2017	No	Sponsor
32	16/LO/1605	201385	HyPeR: A Phase 1, Dose Escalation Study of Guadecitabine (SGI-110) a Second Generation Hypo-Methylating Agent in Combination with Pembrolizumab (MK3475) in Patients with Refractory Solid Tumours		25/10/2016			02/03/2017		08/03/2017	02/05/2017	No	Sponsor

33	16/LO/1436	205613	Evaluation of Potential Predictors of Disease Progression in Patients with aHUS including Genetics, Biomarkers, and Treatment.	14/09/2016	29/11/2016	29/11/2016		08/06/2017		12/06/2017	16/06/2017	No	Sponsor
34	16/LO/1641	210606	A Phase 1/2a, open-label multicenter study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of PEN-221 in patients with somatostatin receptor 2 expressing advanced cancers, including gastroenteropancreatic or lung or thymus or other neuroendocrine tumors or small cell lung cancer or large cell neuroendocrine carcinoma of the lung		30/09/2016	20/01/2017		13/02/2017		14/02/2017	19/04/2017	No	Neither
35	16/WM/0406	210454	Red cell transfusion in Acute myeloid Leukaemia	01/11/2016	10/11/2016	08/11/2016		12/12/2016		21/12/2016	15/06/2017	No	Neither
36	16/NE/0353	211988	A randomized, double-blind, placebo-controlled Phase III study of ODM-201 versus placebo in addition to standard androgen deprivation therapy and docetaxel in patients with metastatic hormone-sensitive		23/09/2016	19/12/2016		21/03/2017		23/03/2017	10/05/2017	No	Sponsor

			prostate cancer									

37	17/EM/0032	209811	Reclassifying constipation using magnetic resonance imaging combined with high resolution manometry: a validation study and double-blind crossover trial (RECLAIM study)	09/12/2016	07/03/2017			20/04/2017		26/04/2017		No	Sponsor

38	16/LO/0986	202286	A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer	21/12/2016	16/02/2017	10/08/2016		05/04/2017		12/04/2017		No	Neither
39	16/LO/2018	219534	A Multi-Centre, Open Label, Phase IIb Study, Evaluating the Safety, Tolerability and Efficacy of Targeted Intraprostatic Administration of PRX302 to Treat Men with Histologically Proven, Clinically Significant, Localised, Low- to Intermediate-Risk Prostate Cancer that is Associated with an MRI Lesion	23/01/2017	24/01/2017							No	Sponsor
40	17/LO/0247	213278	A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects with Advanced or Metastatic Solid Tumour	26/10/2016	06/02/2017	24/05/2017						No	Sponsor
41	16/SC/0657	182046	A Phase Ib/II combination of acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for patients with Diffuse Large B-cell Lymphoma (DLBCL)	20/03/2017	22/03/2017	28/02/2017		23/05/2017		23/05/2017		No	Sponsor
42	16/SC/0590	191279	DEpletion of Serum amyloid P component In Alzheimer?s Disease: DESPIAD. Double-blind placebo controlled randomised phase IIb trial of SAP depletion by CPHPC in mild Alzheimer?s disease	12/12/2016	02/03/2017	16/02/2017		09/05/2017		25/05/2017		No	Sponsor

43	16/EM/0380	198726	A phase II, multicentre, randomised trial comparing combination gemcitabine/carboplatin and hydroxychloroquine versus carboplatin/etoposide therapy alone in small cell lung cancer (SCLC)		10/11/2016	09/11/2016		18/01/2017		20/01/2017		No	Sponsor
44	17/WS/0059	211178	A Randomized Phase 2 Trial of Neoadjuvant and Adjuvant Therapy with the IRX-2 Regimen in Patients with Newly Diagnosed Stage II, III or IVA Squamous Cell Carcinoma of the Oral Cavity	10/03/2017	09/03/2017							No	NHS Provider
45	16/LO/1999	200065	A comparison of Cognitive Behaviour Therapy for insomnia (CBTi) and usual audiological rehabilitation in the management of tinnitus related insomnia		17/01/2017	09/02/2017		24/02/2017		24/02/2017		No	Sponsor
46	16/LO/2141	200571	Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication	26/01/2017	03/03/2017	06/04/2017		17/05/2017		29/06/2017		No	Sponsor
47	17/EE/0205	224373	A Phase I Open-Label Dose Escalation Study to Determine the Efficacy, Safety and Pharmacokinetics of GMI-1271 as Adjunct to Standard of Care Chemotherapy for the Treatment of Multiple Myeloma	16/11/2016	15/03/2017							No	Neither

48	12/EE/0274	88262	Tranexamic Acid for the treatment of significant traumatic brain injury: an international, randomised, double blind, placebo controlled trial.		29/03/2017	18/08/2016						No	Sponsor
49	17/LO/0285	211245	Phase 1/2 Safety, Pharmacokinetic, and Antitumor Activity Study of G1T38 in Combination with Fulvestrant in Patients with Hormone Receptor-Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer after Endocrine Failure	05/12/2016	24/02/2017	05/04/2017		15/05/2017		25/05/2017		No	Neither
50	16/SC/0566	213579	A PROSPECTIVE INTERNATIONAL MULTICENTRE RANDOMISED CONTROLLED SINGLE BLIND CLINICAL INVESTIGATION OF MAGNETICALLY ENHANCED DIFFUSION FOR ACUTE ISCHAEMIC STROKE (MEDIS-INTERNATIONAL)		15/12/2016	10/01/2017		07/03/2017		07/03/2017		No	Sponsor
51	16/NE/0183	197040	Treatment of Poor-grade Subarachnoid Haemorrhage Trial 2	08/11/2016	31/01/2017	13/07/2016		25/04/2017		27/04/2017		No	Sponsor
52	17/SC/0033	218114	A phase 3 randomized, open-label, multicenter study comparing isatuximab (SAR650984) in combination with pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose	11/10/2016	19/01/2017	29/03/2017		13/04/2017		13/04/2017		No	Sponsor

			dexamethasone in patients with refractory or relapsed and refractory multiple myeloma										
53	15/WM/0261	183481	Anticoagulants for Living FoEtuses in women with recurrent miscarriage and inherited thrombophilia : ALIFE 2	22/08/2016	28/12/2016	15/06/2016		23/03/2017		30/06/2017		No	Sponsor
54	17/LO/0284	221453	A study of single doses to evaluate the safety, tolerability, pharmacokinetics and target engagement of nebulised GSK3008348 in idiopathic pulmonary fibrosis patients, using positron emission tomography (PET) imaging	21/03/2017	15/02/2017			11/05/2017		12/05/2017		No	Sponsor
55	17/SC/0185	214076	A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton?s Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects with Waldenstr?m?s Macroglobulinemia (WM)	10/11/2016	18/04/2017							No	Sponsor
56	16/WS/0197	186191	An adaptive multi-arm phase II trial of maintenance targeted therapy after chemotherapy in metastatic urothelial cancer	03/02/2017	16/02/2017			18/05/2017		02/06/2017		No	Sponsor

57	16/LO/1312	188434	A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400-211 in Patients with Dermatomyositis		13/10/2016	02/12/2016		13/01/2017		19/01/2017		No	Sponsor
58	16/SC/0304	166367	A Study into the Pharmacodynamic Biomarker Effects of Olaparib (a PARP Inhibitor) ? Degarelix (a GnRH antagonist) given Prior to Radical Prostatectomy		01/11/2016	16/08/2016		09/02/2017		10/02/2017		No	Sponsor
59	16/LO/2150	201093	Randomised phase II Trial of olaparib, chemotherapy or olaparib and cediranib in patients with BRCA mutated platinum?resistant ovarian cancer	25/11/2016	27/01/2017			12/05/2017		12/05/2017		No	Sponsor
60	16/LO/1502	178292	Utilising Circulating Tumour Cell (CTC) Counts to Optimize Systemic Therapy of Metastatic Prostate Cancer: CTC-STOP Trial	16/01/2017	16/01/2017	07/10/2016		02/05/2017		27/04/2017		No	Sponsor
61	17/LO/0475	220177	The Clinical And Biological effects of the use of pRobIOtic VSL#3 in patients with oral lichen planus: a proof-of-concept study (CABRIO)		12/04/2017	12/04/2017		18/05/2017		25/05/2017		No	Sponsor
62	16/SC/0271	187103	The UK Plasma based Molecular Profiling of Advanced Breast Cancer to inform Therapeutic Choices (plasmaMATCH) Trial: A multi parallel cohort, open-label, multi-centre phase IIa clinical trial aiming to provide proof of principle efficacy for designated targeted therapies in patients with advanced breast cancer where the targetable mutation is identified through ctDNA screening		12/10/2016	21/09/2016		27/01/2017		02/02/2017		No	Sponsor

63	17/LO/0011	217376	VEROnA: A pilot, open label, single-arm, window of opportunity study of vandetanib-eluting radio-opaque embolic beads (BTG 002814) in patients with resectable hepatocellular carcinoma and in patients with resectable liver malignancies	22/11/2016	19/01/2017	15/02/2017		08/05/2017		09/05/2017		No	Sponsor
64	16/LO/1628	199315	The ACL SNNAP Trial: ACL Surgery Necessity in Non Acute Patients. Comparison of the clinical and cost effectiveness of two management strategies for non-acute Anterior Cruciate Ligament (ACL) injury: Rehabilitation versus surgical Reconstruction.		01/11/2016	23/08/2016		21/02/2017		21/02/2017		No	Sponsor
65	16/NW/0379	200426	LY2801653 and LY3009806 - Advanced or Metastatic Biliary Tract Cancer	16/05/2016	13/07/2016			15/11/2016		30/11/2016		No	Both
66	14/WM/1260	163072	A phase Ib study to assess the safety and tolerability of oral Ruxolitinib in combination with 5azacitidine in patients with advanced phase myeloproliferative neoplasms (MPN), including myelodysplastic syndromes (MDS) or acute myeloid	15/02/2017	21/04/2017	27/08/2016		27/04/2017		10/05/2017		Within 70 Days	Sponsor

			leukaemia (AML) arising from MPN										
67	16/NW/0305	201856	A PHASE III, MULTICENTRE, RANDOMISED, DOUBLE BLIND, PARALLEL GROUP, PLACEBO CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONE OR MORE INTRADETRUSOR TREATMENTS OF 600 OR 800 UNITS OF DYSPORT? FOR THE TREATMENT OF URINARY INCONTINENCE IN SUBJECTS WITH NEUROGENIC DETRUSOR OVERACTIVITY DUE TO SPINAL CORD INJURY OR MULTIPLE SCLEROSIS	14/07/2016	18/07/2016	28/07/2016		02/12/2016		08/12/2016		No	Sponsor
68	16/EE/0234	194284	Three versus five years of adjuvant imatinib as treatment of patients with operable GIST with a high risk of recurrence: A randomised phase III multi-centre study by the Scandanavian Sarcoma Group	21/06/2016	06/07/2016	12/09/2016		16/12/2016		28/12/2016		No	Sponsor
69	16/LO/1960	199019	An Open-label, Sequential, Ascending, Repeated Dose-finding Study of Sarilumab, administered with Subcutaneous (SC) Injection, in Children and Adolescents, Aged 1 to 17 years, with Systemic Juvenile Idiopathic Arthritis (sJIA), Followed by an Extension Phase	07/11/2016	07/03/2017	28/02/2017		07/03/2017		20/04/2017		No	Neither

70	16/LO/2008	208047	A Single Arm, Open-Label, Multi-Centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO2, a CAR T Cell Treatment Targeting BCMA and TACI, in Patients with Relapsed or Refractory Multiple Myeloma	13/06/2016	15/11/2016	31/03/2017		03/05/2017		03/05/2017		No	Sponsor
71	17/NE/0115	218417	MULTICENTER, INTERNATIONAL, DOUBLE-BLIND, TWO-ARM, RANDOMIZED, PLACEBO-CONTROLLED PHASE II TRIAL OF PIRFENIDONE IN PATIENTS WITH UNCLASSIFIABLE PROGRESSIVE FIBROSING ILD	16/01/2017	17/04/2017	26/05/2017		23/06/2017				No	Sponsor
72	17/WM/0017	201600	A randomised placebo-controlled trial of mifepristone and misoprostol versus misoprostol alone in the medical management of missed miscarriage (MifeMiso trial)	16/02/2017	11/04/2017	06/04/2017		27/06/2017				No	Sponsor
73	17/EM/0063	213979	A Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial of the FLT3 Inhibitor Gilteritinib (ASP2215) Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects with FLT3/ITD AML in First Complete Remission	13/10/2016	15/03/2017	27/04/2017		23/05/2017		02/06/2017		No	Sponsor

74	17/WM/0105	214955	A Phase 1/2 dose Escalation and Expansion Study to Investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with Fulvestrant in subjects with ER+ breast cancer	27/10/2016	08/03/2017			31/05/2017		01/06/2017		No	Neither
75	15/LO/0114	160295	A Cancer Research UK Phase I study of MOv18 IgE, a first in class chimeric IgE antibody against folate receptor-a, in patients with advanced solid tumours	23/02/2017	16/03/2017			14/06/2017		15/06/2017		No	Sponsor
76	16/LO/1810	209789	A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL)	10/02/2017	02/03/2017	03/01/2017		09/06/2017		16/06/2017		No	Sponsor
77	17/NE/0058	219540	A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors	24/02/2017	27/02/2017	13/04/2017		14/06/2017				No	Sponsor
78	17/NW/0175	222859	Phase 1b Open-Label, Dose Escalation Study of PRTX-100 in Adult Patients with Persistent/Chronic Immune Thrombocytopenia	07/03/2017	06/03/2017			27/06/2017		27/06/2017		No	Sponsor

79	16/LO/1004	207544	Efficacy and safety of low-dose IL-2 (ld-IL-2) as a Treg enhancer for anti-inflammatory therapy in newly diagnosed Amyotrophic Lateral Sclerosis (ALS) patients: A randomized, double-blind, placebo- controlled, phase-II Proof of Concept/ Proof of Mechanism Clinical Trial	06/09/2016	20/02/2017			19/06/2017				No	Sponsor
80	17/LO/0440	217506	Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of Intrathecally Administered ISIS 814907 in Patients with Mild Alzheimer's Disease	26/04/2017	26/04/2017	20/06/2017						Within 70 Days	
81	17/LO/0795	220512	A Phase I/II trial investigating the combination of Pembrolizumab (Keytruda) with Cyclophosphamide and Lenalidomide (Revlimid) for patients with relapsed multiple myeloma	03/05/2017	04/05/2017							Within 70 Days	
82	16/YH/0157	204585	PersonaLising Anal cancer radioTherapy dOse ? Incorporating ACT3, ACT4 and ACT5	05/05/2017	05/05/2017							Within 70 Days	
83	17/EM/0166	222665	A Phase 2a trial of Avelumab, an anti-PD-L1 antibody, in relapsed and refractory peripheral T-cell lymphoma (PTCL)	05/05/2017	05/05/2017							Within 70 Days	

84	17/EM/0155	206803	POINT: Multicenter, randomized, double-blind, parallel-group, add-on, superiority study to compare the efficacy and safety of ponesimod to placebo in subjects with active relapsing multiple sclerosis who are treated with dimethyl fumarate (Tecfidera?)	05/05/2017	09/05/2017							Within 70 Days	
85	17/EM/0183	220783	A randomised Phase III study to assess the clinical efficacy and safety of 100 mg SC Mepolizumab as an add on to maintenance treatment in adults with severe bilateral Nasal Polyposis	27/02/2017	11/05/2017							Within 70 Days	
86	17/SC/0055	219468	A three-part randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of secukinumab treatment in Juvenile Idiopathic arthritis subtypes of psoriatic and enthesitis-related arthritis	09/05/2017	16/05/2017	27/03/2017						Within 70 Days	
87	17/LO/0741	216587	Multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of GZ/SAR402671 inpatients with early-stage Parkinson?s disease carrying a GBA mutation or other prespecified variant (DEME 33640)	19/12/2016	18/05/2017							Within 70 Days	

88	16/EE/0546	210292	Barrett?s Oesophagus Trial 3 (BEST3): Cluster randomised controlled trial comparing the Cytosponge-TFF3 test with usual care to facilitate the diagnosis of oesophageal pre-cancer in primary care	16/05/2017	19/05/2017							Within 70 Days	
89	17/NE/0165	217768	AN OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB IN PATIENTS WITH EARLY STAGE RELAPSING REMITTING MULTIPLE SCLEROSIS	13/10/2016	22/05/2017							Within 70 Days	
90	17/LO/0736	225746	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BMS-986168 in Participants with Progressive Supranuclear Palsy with an Open-Label Extension	27/09/2016	22/05/2017							Within 70 Days	
91	17/LO/0038	182633	A Randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours	08/03/2017	23/05/2017							Within 70 Days	
92	17/EE/0120	220317	To study the role of nicotinamide riboside in inducing mitochondrial biogenesis	08/03/2017	23/05/2017	23/05/2017						Within 70 Days	

93	17/EM/0152	216307	A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML	17/11/2016	23/05/2017							Within 70 Days	
94	17/LO/0728	224333	OPEN-LABEL, SINGLE-ARM, MULTICENTER, LONG-TERM STUDY TO EVALUATE SAFETY AND EFFICACY OF BRIVARACETAM USED AS ADJUNCTIVE TREATMENT IN PEDIATRIC SUBJECTS WITH EPILEPSY	10/05/2017	25/05/2017							Within 70 Days	
95	16/LO/0423	198451	A PHASE 1 TRIAL OF SRA737 (A CHK1 INHIBITOR) ADMINISTERED ORALLY IN SUBJECTS WITH ADVANCED CANCER	04/04/2017	25/05/2017							Within 70 Days	
96	17/YH/0181	227102	Phase 2 Study of TAK-659 in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma After at Least 2 Prior Lines of Chemotherapy	21/04/2017	30/05/2017							Within 70 Days	
97	17/NW/0312	211974	Phase II study of cabozantinib in patients with metastatic gastrointestinal stromal tumor (GIST) who progressed during neoadjuvant, adjuvant or palliative therapy with imatinib and sunitinib	10/05/2017	01/06/2017							Within 70 Days	
98	17/NW/0317	224142	A feasibility study to evaluate the acceptability of Krio, a food for special medical purposes (FSMP) for use in the ketogenic diet (KD) with regard to product tolerance, compliance and acceptability	30/03/2017	02/06/2017							Within 70 Days	

99	17/LO/1043	226184	A Phase 1/2 Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Azacitidine in Combination With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors and Previously Treated Stage IIIB or Stage IV Non?Small Cell Lung Cancer and Stage IV Microsatellite-Stable Colorectal Cancer	14/02/2017	06/06/2017							Within 70 Days	
100	17/ES/0051	223060	A Phase II Open-Label Study of NUC-1031 in Patients with Platinum-ResistantOvarian Cancer	08/06/2017	07/06/2017							Within 70 Days	
101	17/NW/0330	222996	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of AG-120 in Previously-treated Subjects with Nonresectable or Metastatic Cholangiocarcinoma with an IDH1 Mutation	26/07/2016	12/06/2017							Within 70 Days	
102	16/SC/0584	198941	A randomised phase II double-blinded placebo-controlled trial of intravenous immunoglobulins and rituximab in patients with antibody-associated psychosis (SINAPPS2)	12/06/2017	12/06/2017							Within 70 Days	

103	16/LO/0422	198606	A Phase 1 Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Gemcitabine plus Cisplatin or Gemcitabine Alone in Subjects with Advanced Cancer	04/04/2017	14/06/2017							Within 70 Days	
104	17/EE/0264	228153	A Phase III, Randomized, Multi-Center, Open-Label, Comparative Global Study to Determine the Efficacy of Durvalumab Or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Patients With Metastatic Non Small-Cell Lung Cancer	11/05/2017	16/06/2017							Within 70 Days	
105	16/LO/1495	207629	Phase III mechanistic, randomised controlled trial of Stopping Perioperative Angiotensin II Converting Enzyme inhibitors and/or receptor blockers in major noncardiac surgery	15/03/2017	16/06/2017							Within 70 Days	
106	17/SW/0127	225959	A multicentre randomised trial of First Line treatment pathways for newly diagnosed Immune Thrombocytopenia: Standard steroid treatment versus combined steroid and mycophenolate.	19/06/2017	19/06/2017							Within 70 Days	

107	17/LO/0427	199962	A Phase I/II Trial of Combination Nab-Paclitaxel and Nintedanib or Nab-Paclitaxel and Placebo In Relapsed NSCLC Adenocarcinoma	05/04/2017	20/06/2017							Within 70 Days	
108	17/LO/0893	211137	A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin?s Lymphoma	03/02/2017	26/06/2017							Within 70 Days	
109	16/LO/0609	194191	Acceptance and Commitment Therapy for Muscle Disease (ACTMUS)	02/05/2017	26/06/2017	30/06/2016						Within 70 Days	
110	14/LO/0578	140363	Autism-spectrum disorders: treating co-morbid social anxiety disorder with adapted cognitive behaviour therapy	31/05/2017	28/06/2017							Within 70 Days	
111	16/WM/0472	211270	CheckpOiNt blockade For Inhibition of Relapsed Mesothelioma (CONFIRM): A Phase III Trial to Evaluate the Efficacy of Nivolumab in Relapsed Mesothelioma	26/04/2017	04/05/2017	14/03/2017		07/06/2017				Within 70 Days	
112	17/WM/0106	201079	MOTILITY: Small bowel motility quantified by cine MRI as a predictor of long term response in patients with Crohn?s disease commencing biological therapy	27/01/2017	08/05/2017	28/04/2017		02/06/2017		13/06/2017		Within 70 Days	
113	17/LO/0769	218626	Face to face structured education group versus audio-visual information in Irritable Bowel Syndrome: a randomised controlled trial	12/05/2017	25/05/2017	12/05/2017		02/06/2017		02/06/2017			

114	17/LO/0494	224195	A Phase 3 Single Arm Study Evaluating the Efficacy and Safety of Gene Therapy in Subjects with Transfusion-dependent ?-Thalassemia, who have a ?0/?0 Genotype, by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo with a Lentiviral ?A-T87Q-Globin Vector in Subjects =50 Years of Age	28/03/2017	08/06/2017	24/05/2017		28/06/2017		30/06/2017			

Delivering Clinical Research

ID	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial

1	13/LO/1682	140185	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients with Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal	Number Agreed	6	6	Date Agreed	01/12/2016	18	29/07/2016	18	Recruitment Finished
2	13/NW/0830	140382	A phase I study of Human Pharmacokinetics and Safety of ORY1001, and LSD1 inhibitor, in relapsed or refractory acute leukaemia (AL)	Number Agreed	2	2	Date Agreed	01/03/2015	2	01/09/2016	2	Withdrawn By Sponsor
3	13/LO/1838	134368	An open label, phase II, randomized, pilot study to assess the efficacy in term of erythroid improvement of deferasirox combined with erythropoietin compared to erythropoietin alone in patients with lowand int-1-risk myelodysplastic syndrome	Number Agreed	3	3	Date Agreed	01/09/2015	0	01/09/2016	0	Recruitment Finished
4	15/LO/0924	173624	A Double-blind, Randomized, Placebo-controlled Phase 3 Study of Orally Administered PLX3397 in Subjects with Pigmented Villonodular Synovitis or Giant Cell Tumor of the Tendon Sheath	Number Agreed	3	3	Not Available / Not Agreed			09/09/2016	3	Withdrawn By Sponsor
5	15/EE/0460	193953	Evaluation of a Novel Electronic Transanal Irrigation System - Navina Smart	Number Agreed	16	16	Not Available / Not Agreed			01/10/2016	16	Recruitment Finished
6	14/SC/1167	144247	Phase 3, Randomised, PlaceboControlled, Doubleblind, MultiCentre, TwoPart Study of Patritumab (U31287) in Combination with Erlotinib in EGFR Wildtype Subjects with Locally Advanced or Metastatic Non-	Number Agreed	5	5	Date Agreed	31/10/2014	2	06/11/2016	2	Withdrawn By Sponsor

			Small Cell Lung Cancer (NSCLC) Who Have Progressed on at									
7	14/NE/1175	164135	Open Label, Adaptive Design, Ascending, Multiple-Dose Study to Evaluate Safety and Efficacy of BMS-986004 (Anti-CD40L dAb) in Adult Subjects with Primary Immune Thrombocytopenia (ITP)	Number Agreed	2	2	Date Agreed	01/06/2016	0	08/11/2016	0	Withdrawn By Sponsor
8	13/WM/0373	135259	A Phase 3 Switchover Study of the Efficacy and Safety of BMN 701 (GILT-tagged Recombinant Human GAA) and Long-Term Study for Extended Treatment in rhGAA Exposed Subjects with Late-onset Pompe Disease	Number Agreed	3	3	Date Agreed	01/06/2015	1	24/11/2016	1	Withdrawn By Sponsor
9	16/LO/0951	203461	A PHASE II PILOT STUDY TO EVALUATE THE SAFETY, TOLERABILITY, EFFICACY, PHARMACODYNAMICS AND PHARMACOKINETICS OF IDES IN ASYMPTOMATIC ANTIBODY-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) PATIENTS WITH LOW ADAMTS13 ACTIVITY	Number Agreed	2	2	Not Available / Not Agreed			27/12/2016	2	Withdrawn By Sponsor
10	15/LO/0009	146896	A Prospective Development Study evaluating Focal Therapy using Encage? Coiled Bipolar Radiofrequency Ablation in Men with Localised Prostate Cancer	Number Agreed	20	20	Not Available / Not Agreed			28/02/2017	23	Recruitment Finished
11	14/SC/1340	17797	A Multicenter, Multinational, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/day) as Treatment in Patients with Huntington's	Number Agreed	10	10	Date Agreed	27/11/2015	10	05/04/2017	10	Recruitment Finished

			Disease									
12	13/EM/0373	15394	An Open-label, Multicenter, Phase 2 Study of Oral MLN9708 in Adult Patients With Relapsed and/or Refractory Follicular Lymphoma	Number Agreed	3	3	Date Agreed	01/01/2015	1	25/04/2017	1	Recruitment Finished
13	16/SC/0076	199027	A Pilot Double-blind, Placebo-controlled Crossover Study to Explore the Possible Benefit of AUT00063, an Oral Modulator of Voltage-gated Potassium Channels, in Adult Post-lingual Unilateral Cochlear Implant	Number Agreed	8	8	Not Available / Not Agreed			27/03/2017	2	Recruitment Finished